For patients facing a lung disease, including COPD, current and traditional therapeutic options may not be as effective in managing symptoms or slowing the progression of the condition so researchers have turned their attention to the potential benefits of stem cell therapy and ex vivo lung bioengineering in hopes of developing new and effective therapeutic approaches to treat lung disease.
Demonstrating a rapid progression over the last decade, the development of stem cell therapies and bioengineering approaches for lung disease has primarily shifted focus to the application of immunomodulatory and paracrine actions of mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) and the field of ex vivo lung bioengineering.
In this manuscript, Weiss reviews clinical trials in lung disease and provides the current progress for a variety of therapeutic options. Specific treatments reviewed include:
Structural Engraftment of Circulating or Exogenously Administered Stem Cells
Ex Vivo Derivation of Lung Epithelial Cells from Embryonic Stem Cells or Induced Pluripotent Stem Cells (iPS)
Endogenous Lung Stem and Progenitor Cells
Endothelial Progenitor Cells
MSCs and Immunomodulation of Lung Disease
The author points out that although preclinical literature supports the use of EPCs and MSCs in acute lung injury and/or chronic inflammatory and immune-mediated conditions (including asthma, bronchiolitis, obliterans, and bronchopulmonary dysplasia), these preclinical models are not always predictive of clinical behaviors. As such, clinical investigations of these cell-based therapies for lung disease have been slow to develop.
Currently, the only effective treatment for severe lung diseases, including BPD, CF, COPD, and IPF, is lung transplantation. With a 50% five-year post-transplant mortality rate, essential lifelong immunosuppression (to prevent chronic lung rejection), and a critical shortage of donor’s lungs, research has turned its attention toward manufacturing surgically implantable ex vivo (or “outside the living body”) lung tissue. While several challenges still exist, recent significant progress has been made using both synthetic and donor tissue in generating ex vivo tissue for use in various lung treatment applications.
The author concludes that while exciting progress has been made in the field of stem cell therapy and ex vivo generation of tissue to treat lung diseases, much research is still on the horizon. Within future research, they hope to better understand the identity of endogenous lung airway, the development of functional airway and alveolar epithelial cells from ESCs and iPS cells, and a better understanding of the physiologic and pathophysiologic roles of EPC and Fibrocytes in lung diseases.
The use of stem cell therapy and ex vivo lung bioengineering offers tremendous potential for the treatment of lung diseases, however, the clinical use of artificial engineered or decellularized scaffolds for use in treating lung disease is likely to be several years off.
Chronic obstructive pulmonary disease (COPD) affects 250 million people each year and is the cause of nearly 5% of deaths globally. This family of airway obstruction conditions is characterized by the loss of lung tissue and airway obstruction caused by chronic inflammation of the airways. As a result, components of the lungs, including the alveoli, are destroyed over time. Using regenerative medicine, including stem cell therapy, can address the damage caused by these conditions.
What Is COPD?
COPD is a progressive disorder that makes breathing very difficult. As the airways become obstructed, patients may experience symptoms such as mucus production, wheezing, cough, and difficulty breathing. Smoking is believed to be the cause of 85 to 90% of COPD cases, though factors such as long-term exposure to pollution or irritants could also contribute to the conditions.
The two main types of COPD are emphysema and chronic bronchitis. In emphysema, the alveoli at the end of the air passageways are destroyed by exposure to cigarette smoke or other irritants. In chronic bronchitis, the bronchial tubes become inflamed, which carry air to and from the air sacs.
Currently, there are several types of medications available to help control flare-ups of COPD, but each patient responds differently to treatments. There are also oxygen therapies available to aid patients with low blood oxygen levels and to provide easier breathing.
Stem Cell Therapy for COPD
Stem cell therapy is a natural alternative to other medications that have caused serious side effects or failed to produce measurable improvements. Through this regenerative medicine approach, patients’ air sacs and damaged lung tubes have the potential to be repaired, lung capacity increased and improved breathing.
Stem cells are the building blocks of the body due to their ability to regenerate and transform into virtually any specialized cell type. Through this treatment, stem cells are sourced by either the patient or an umbilical cord donor and re-delivered through direct injection, intravenously, and/or through a special nebulizer via inhalation. Depending on the patient’s condition, additional treatments may be needed. After stem cell therapy, COPD patients may be advised to undergo post-treatment lung rehabilitation to promoted optimal treatment outcomes.
Stem cell therapy continues to be an active topic in regenerative medicine research. It is not a cure and it may not be right for all patients with COPD, but it could be a promising alternative to anyone who is looking for other options outside of treatments with severe side effects or those that haven’t shown beneficial outcomes. If you are interested in learning more about Stem cell therapy for COPD contact a care coordinator today!
Several recent studies have shown that adult stem cells, and specifically mesenchymal stem cells (MSC), appear to support the regeneration and protection of lung tissue, making them a very promising potential next-generation therapy option for the treatment of COPD.
Known treatments for COPD are designed to address symptoms and not the actual cause of the condition; considering that COPD continues to be among the leading causes of death among developed countries and that it’s considered to be a preventable and treatable disease there is a clear and compelling need to develop more effective therapeutic strategies.
As COPD develops, its inflammatory properties are characterized by the death of the epithelial cells, loss of the terminal air-space within the lung, and ongoing breakdown of lung tissue responsible for stability, elastic recoil, and other physiological functions essential for respiration.
Since the damage to these cells is permanent and not repairable, researchers continue to explore the use of MSCs as a potential option to repair and restore lung structure and lung function in people living with COPD.
Currently, any therapeutic-based COPD treatment option relies on the continued use of bronchodilators and/or corticosteroids to reduce the symptoms of COPD. While both of these drugs have been able to slow the worsening of COPD symptoms, the benefits appear to be ineffective as a long-term treatment option for even mild to moderate COPD.
Because of their capacity to induce growth of skeletal muscle cells, blood, fat, vascular systems, and connective tissues throughout the body, and since they seemingly have a capacity for self-renewal, MSCs are now being considered as a therapeutic treatment option for COPD.
In addition to their versatility throughout various cells, tissues, and systems, MSCs are relatively simple to isolate, they expand with high efficiency, are easily able to be processed and transported from the lab setting to point-of-use, and are highly compatible with different delivery methods and formulations currently being used by medical professionals.
Early research has also demonstrated that MSCs possess powerful immunosuppressive properties and are easily able to seek out and migrate to specific sites of tissue injury; this appears to be especially promising in the tissue of the lungs where not only have MSCs demonstrated the ability to suppress inflammation and growth factor production but also been found to reduce fluid retention within the lungs.
While these findings are promising, Phase II clinical trials to establish the use of Mesenchymal stem cells as a therapeutic treatment in patients with severe COPD are currently ongoing. Specifically, this trial is examining how effective MSCs derived from normal healthy adult donors in the treatment of COPD.
Although further study is required, early indications show promise that stem cell therapy, and specifically the use of MSCs, could be a very effective therapeutic treatment option in patients with moderate to severe COPD.
Chronic obstructive pulmonary disease (COPD) is a lung condition that makes it hard for patients to breathe. In COPD, small airways in the lungs thicken and lose their elasticity. People with COPD have shortness of breath, especially during physical activity. Patients with severe COPD may experience a more challenging quality of life. COPD patients may experience several exacerbations a year which require a stay in the hospital.
Patients with COPD typically need one or more inhalers a day. These inhalers help to open airways and, in some cases, decrease lung inflammation. Patients who also have bronchiectasis may need to take an oral antibiotic every day. During a COPD exacerbation, patients usually must receive powerful steroid treatments intravenously, routine breathing treatments, and supplemental oxygen.
People with COPD are more prone to lung infections, and so they usually receive IV antibiotics for pneumonia. Those who successfully stop smoking can help to prevent further lung damage, however, the inflammation and lung damage persists for a long time. Today, patients are seeking alternative therapies for COPD. Many are discovering regenerative medicine, also known as stem cell therapy, that may offer an incredibly promising therapy for COPD.
The lungs have a large number of naturally occurring stem cells that can restore function. For example, mice who lose half their lung capacity from experimental COPD survive, and natural stem cells within the lungs can restore their lungs to a natural state within 5 months. Unfortunately, humans with COPD cannot repair their lungs as quickly and as fully as mice can. This is why researchers are studying the use of stem cell treatment to restore lung function in patients with COPD.
Studies have shown that stem cells have the potential to help improve lung function. Stem cell treatment improved oxygen and carbon dioxide exchange, exercise tolerance, and cell injury in early studies.
One review did show that stem cell treatment is “safe and may improve patients’ condition and quality of life; however, larger-scale studies are needed to evaluate efficacy.” More research in humans is needed, but the pre-clinical (aka animal and laboratory) research in this area is quite promising.
Reference: Kokturk N, Yıldırım F, Gülhan PY, Oh YM. Stem cell therapy in chronic obstructive pulmonary disease. How far is it to the clinic?. Am J Stem Cells. 2018;7(3):56-71. Published 2018 Aug 1.
Chronic obstructive pulmonary disease (COPD) is a lung condition in which airflow to and from the lungs is obstructed, making it increasingly difficult to breathe. The World Health Organization estimates that the condition is the third-leading cause of mortality worldwide. There is currently no cure for COPD, although there is a COPD treatment available to help control its progression.
Recently, researchers have begun to study regenerative medicine approaches, which may be used to treat COPD and actually reverse some of the damage already done to the lungs. Stem cell therapy is one particularly promising option.
How Can Stem Cells Be Used as a COPD Treatment?
Stem cells act as the foundation for all cell types. They have the ability to proliferate and transform into adult cells and can repair injuries. They also have regenerative properties and can therefore help heal compromised lung tissue.
At the site of a wound, stem cells differentiate and release pro-inflammatory cytokines and growth factors to help draw healing proteins to the injury. Because the stem cells themselves are anti-inflammatory and anti-fibrosis (meaning they reduce the formation and build-up of scar tissue), they appear to be particularly useful for treating conditions, such as COPD.
How Are Patients Responding to Stem Cell Therapy for COPD?
While clinical trials and studies are still ongoing, stem cell therapy has provided patients with improvements in quality of life, such as improved energy levels, improved sleep quality, and reduction in the rate of tissue damage, and restoration of lung structure and function.
What Is the Process for Stem Cell Therapy for COPD?
Patients who are eligible candidates for stem cell therapy can either have stem cells retrieved from their own tissue, such as fat tissue or donated from umbilical cord tissue. The process is quick, simple, and painless. Stem cell therapy is well-tolerated in the majority of cases, is considered to be safe, and offers a potential alternative option for patients to consider. Contact a Care Coordinator today for a free assessment!
A decline in lung function can be both age-related and result from a disease, such as chronic obstructive pulmonary disease (COPD). Although there are medications available to help patients manage the symptoms of COPD, the disease has no cure. Thus, for both age-related and COPD-related decline in lung function, patients are limited in terms of their treatment options.
Recently, researchers discovered a potential therapy in flavonoids for improving lung function. This group of phytonutrients is found in nearly all vegetables and fruits and is known to have powerful antioxidants and anti-inflammatory properties. While there have been plenty of previous research showcasing flavonoids’ abilities in medical applications, studies on their effect on lung function have been limited.
In the most recent research, investigators focused on anthocyanins, a type of flavonoid which has been found in lung tissue shortly after being ingested. Based on findings, it appears that the plant chemicals may play an important role in minimizing mucus and inflammatory secretions. Study participants who consumed the most anthocyanins experienced improvements in a number of key lung function indicators over their peers, including a slower rate of decline in FEV1, which measures how much air a person can exhale in a second. They also experienced a slower rate of decline in FVC, the amount of air exhaled after taking a deep breath. Benefits were realized across people who had smoked as well as those who had not.
Good Sources of Anthocyanins
While the researchers note that quitting is the best choice smokers can make to improve their lung function, a diet rich in anthocyanins could be an effective way to boost lung function in former smokers and people who have never smoked. Anthocyanins are found naturally in red onions, berries, grapes, tomatoes, acai, kidney beans, and tart cherries.
Stemedix, Inc. Bayfront Medical Plaza 601 7th Street S. Suite 565 Saint Petersburg, FL 33701, USA
This website and its contents are not intended to treat, cure, diagnose, or prevent any disease. Stemedix, Inc. shall not be held liable for the medical claims made by patient testimonials or videos. They are not to be viewed as a guarantee for each individual. The efficacy for some products presented have not been confirmed by the Food and Drug Administration (FDA).
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.